List of APIs/Active Pharmaceutical Ingredients Companies with Phase 3 Active Clinical Trial - 15

At ALK, we go to work every day to make a difference for the many people with allergies around the world. It is our ambition to make life with allergy surprisingly simple for as many people as possible, and we build upon our strong heritage as a pioneer in allergy immunotherapy, when we continue to innovate, develop and market new products and solutions to help improve the health of people with allergies. Every day, our employees contribute to our aspiration of becoming the world leader in allergy by coming to work to do their best in the pursuit of providing new and better allergy treatments and solutions. We work in a high-energy, international setting where it is imperative that our people thrive and develop. Creativity, influence and opportunities are key elements in developing our people. ALK is a global company with production sites in Denmark, France, Spain and the United States. ALK was founded in Copenhagen in 1923 and today we employ around 2,900 people around the world. Our global headquarters is located in beautiful surroundings in Hørsholm, north of Copenhagen. Read more about ALK at www.alk.net

四川百利天恒药业股份有限公司 百利药业是一家集研发、生产、营销为一体的现代化高新技术企业。拥有2个新药研发中心、1个抗体及ADC药物生产企业、1个化学中间体生产企业及1个化学原料药生产企业、2个化学。

Biolink LifeSciences is a premier contract research organization offering a comprehensive range of services including synthesis, characterization, formulation development, and analytical services for small to large molecules for nearly all dosage forms. Our strength resides with our highly experienced team in synthetic chemistry, analytical method development & validation and formulation development to solve difficult problems.

Entrinsic Bioscience is a biotechnology company that specializes in developing functional ingredients and Active Pharmaceutical Ingredients (APIs) through a proprietary platform centered on amino acid combinations. The company utilizes a biomapping and electrophysiology platform to identify and patent specific amino acid combinations that influence protein regulation and cell signaling. This technology has its origins in research conducted with NASA, aimed at addressing gastrointestinal damage from ionizing radiation during deep space missions. The company offers a range of applications, including products for pulmonary health, digestive health, immune regulation, metabolism, hydration, and skin health. One of its notable products is enterade IBS-D, a non-prescription medical food designed to manage symptoms of IBS-D. Entrinsic collaborates with healthcare providers, academic institutions, and global partners to commercialize its formulations, focusing on science-backed, plant-based solutions that enhance health outcomes.

Givaudan is a global leader in Fragrance & Beauty and Taste & Wellbeing. We celebrate the beauty of human experience by creating for happier, healthier lives with love for nature. Together with our customers we deliver food experiences, craft inspired fragrances, and develop beauty and wellbeing solutions that make people look and feel good. With over 163 locations in 52 countries and over 78 production sites, of which 31 are located in Europe, 22 in North America, 17 in Latin America, 8 in Asia-Pacific, and 1 across South Asia, the Middle East, and Africa, we are committed to driving purpose-led growth that makes a positive impact. Givaudan: Human by nature. www.givaudan.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 22,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

MISSION & VALUES To serve our patients we design affordable, safe and effective therapeutics to safeguard and empower the brain throughout all stages of life. We value partnership and Integrity, we are ethical and responsible and show respect and compassion for our patients. R&D STRATEGY The successful companies of tomorrow are those that go beyond delivering products to delivering real solutions and services. R&D is the cornerstone of our company and we promote ingenuity through an effective intellectual property policy. The advancements in science mean that more targeted, more (cost-)effective treatments are within reach and we are here to take on this challenge. Our innovative R&D is centered on patients’ needs and delivering affordable, safe and effective solutions. Not only will these enable us to improve access to quality healthcare and meet unmet needs, but they will also deliver the sustainable growth required to allow us to continue to invest in innovative research & development. FOCUS Partner in the field of psychiatry and neurology in attentionnal and cognitive enhancement and neurological therapies in particular. These disorders remain largely underdiagnosed and current therapies lack in safety and effectiveness: Attentional Disorders (ADHD, awakening disorders, deficit of alertness) Excessive Daytime Sleepiness (Narcolepsy, Hypersomnias) Pervasive Developmental Disorders (ASD) Cognitive Impairments (MCI, AD) Synucleopathies (PD, LB)

Palvella Therapeutics (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently in clinical development for microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations. For more information, please go to www.palvellatx.com.

Senju Pharmaceutical utilized flexible thinking and a curious mindset to continuously develop new drugs primarily for the global field of ophthalmology. But the true "product" we strive for is happiness - the feeling that can be found with better eyesight.

Servier is a privately held international pharmaceutical company headquartered in France with a passion for innovation that has improved patients' lives around the world. With $4.7 billion in annual sales Servier operates in almost 150 countries worldwide across five therapeutic categories including oncology, cardiovascular, immuno-inflammatory, neuroscience and diabetes. Servier is founded on the principle of serving and governed by an independent non-profit foundation. With this unique operating model, the company can be deliberate about putting patients ahead of profits. In fact, Servier re-invests 25 percent of revenue into research and development each year. Servier is committed to therapeutic progress to serve patient needs and strives to provide future generations with a world where quality healthcare is available and accessible to all. See our community guidelines here: https://www.servier.us/community-guidelines To report a suspected adverse event with a Servier product, please visit: https://www.servier.us/contact-us

SHINPOONG PHARMACEUTICAL CO.,LTD. is a pharmaceuticals company based out of 733-23 Yoksam-Dong,Kangnam-Gu,Seoul, Seoul, South Korea.

Pharmaceutical company focusing on transdermal DDS technology and pain relief therapeutic field

The trillions of microbes that call us home –the human microbiome – perform critical functions that preserve our health including helping develop our immune system, manufacturing nutrients such as vitamins, and harvesting energy from the diet. Alterations of the human microbiome are increasingly recognized as a key factor in autoimmune, metabolic, infectious and many other diseases. For millions of years, humans have co-evolved with this community of microbes, communicating in an ancient language that holds critical clues about how autoimmune and infectious diseases develop. This language is based on a system of signals that our resident microbes use to successfully colonize us, such as byproducts of bacterial metabolism and factors that bacteria use to adapt to human niches. Recent discoveries have shown that most of these signals do not lead to disease, rather, they promote our long-term survival. Vedanta is developing a novel class of therapies that modulate pathways of interaction between the human microbiome and the host immune system. Vedanta was co-founded by PureTech Health and a group of world renowned experts in immunology and microbiology

Wockhardt is a global pharmaceutical and biotechnology organization, providing affordable, high-quality medicines for a healthier world. It is India’s leading research-based global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Specialty Hospitals. Wockhardt is a true Indian Multi-National Company with a multi-ethnic workforce of 3000 Wockhardt Associates from 21 different nationalities globally. It has 3 research centers and 12 manufacturing plants, with businesses ranging from the manufacture and marketing of Pharmaceutical and Bio-pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs) and Vaccines. Headquartered in Mumbai, India, Wockhardt has full-fledged operations in the USA, UK, Ireland and France. It also has its marketing presence in emerging markets of Russia, Brazil, Mexico, Vietnam, Philippines, Nigeria, Kenya, Ghana, Tanzania, Uganda, Nepal, Myanmar, Sri Lanka, Mauritius, Lebanon and Kuwait. Wockhardt’s core business is innovation. It uses science and technology to develop medicines and other products that improve the quality of millions people’s lives through better health. Wockhardt aspires to create a healthier world. Its strategic vision of ‘More & More with Less & Less’ has transformed into new ways of thinking, a new journey for growth, medical breakthroughs for patients and continuing value for all stakeholders.

Zambon is a modern healthcare company founded on the history and values of an Italian family and committed to innovating cure & care to improve patients’ lives. Zambon is present in three different Continents – Europe, America and Asia – with manufacturing units in Italy, Switzerland, France, China and Brazil. Zambon SpA, the pharma subsidiary of the group with its 23 branches, has taken a new role in the industry. In addition to pain and diseases of the respiratory system and urological system, Zambon is establishing a global pipeline and introducing important treatments for serious diseases such as Parkinson’s Disease, Cystic Fibrosis, BOS and NCFB. In recent years, ZBiotech, a specialized biotech company that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through through the scouting, acquisition, licensing and development of new molecules, has also been established. Zambon produces high quality products thanks to the management of the whole production chain which involves Zach-Zambon Chemicals, a privileged partner for API, custom synthesis and generic products. Zambon complements the offering of medicines with modern health solutions, in order to translate its Vision into concrete actions. Zcube - Zambon Research Venture - is actively scouting for modern health solutions in the field of drug delivery systems, medical devices, biomarkers, diagnostics, digital health and big data solutions. In 2018 Zcube established Careapt, a new start-up which develops integrated Hi-Tech/Hi-Touch solutions for chronic disease management. The group also includes ItaliAssistenza, a Home Care Company involved in Patient Support Programs and home care. Zambon was established in 1906 in Vicenza and is headquartered in Milan within OpenZone, the scientific campus where knowledge is shared between partners in the field of Healthcare, founded with the aim to transform research into enterprise.